Home
THAR
THAR News

Latest Tharimmune Inc. (THAR) News on October 29, 2025

ACCESS Newswire

4 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

ACCESS Newswire

5 months ago

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

ACCESS Newswire

6 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

ACCESS Newswire

6 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

ACCESS Newswire

6 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

ACCESS Newswire

6 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

ACCESS Newswire

6 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

ACCESS Newswire

7 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

ACCESS Newswire

7 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

ACCESS Newswire

7 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

ACCESS Newswire

8 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

ACCESS Newswire

9 months ago

Tharimmune to Present at the Microcap Conference 2025

ACCESSWIRE

10 months ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

ACCESSWIRE

a year ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

ACCESSWIRE

a year ago

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

ACCESSWIRE

a year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

ACCESSWIRE

a year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

ACCESSWIRE

a year ago

Tharimmune Announces Upcoming Conference Presentations

ACCESSWIRE

a year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

ACCESSWIRE

a year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

ACCESSWIRE

a year ago

Tharimmune Announces Upcoming Conference Presentations

ACCESSWIRE

a year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

ACCESSWIRE

a year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

ACCESSWIRE

a year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

ACCESSWIRE

a year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

ACCESSWIRE

a year ago

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

ACCESSWIRE

a year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

ACCESSWIRE

a year ago

Tharimmune to Present at 2024 BIO International Convention

ACCESSWIRE

a year ago

Tharimmune Announces 1-for-15 Reverse Stock Split

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management

Newsfile

a year ago

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management

ACCESSWIRE

a year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

ACCESSWIRE

2 years ago

Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

ACCESSWIRE

2 years ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

ACCESSWIRE

2 years ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now

GlobeNewswire

2 years ago

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now

ACCESSWIRE

2 years ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

ACCESSWIRE

2 years ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

ACCESSWIRE

2 years ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

ACCESSWIRE

2 years ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Trxade health, Inc files its 3Q 10Q

GlobeNewswire

2 years ago

Trxade health, Inc files its 3Q 10Q

ESQUIRE FINANCIAL HOLDINGS, INC. ANNOUNCES STRATEGIC FINTECH INVESTMENT IN PAYZLI

PR Newswire

2 years ago

ESQUIRE FINANCIAL HOLDINGS, INC. ANNOUNCES STRATEGIC FINTECH INVESTMENT IN PAYZLI

New to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT

GlobeNewswire

2 years ago

New to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT

Vislink Appoints Christopher DeSalvo as Chief Financial Officer and Vice President of Operations

GlobeNewswire

2 years ago

Vislink Appoints Christopher DeSalvo as Chief Financial Officer and Vice President of Operations

Here's What Could Help EuroDry (EDRY) Maintain Its Recent Price Strength

Zacks

2 years ago

Here's What Could Help EuroDry (EDRY) Maintain Its Recent Price Strength

KWESST Announces Delay in Filing Year-End Reporting Documents

Newsfile

2 years ago

KWESST Announces Delay in Filing Year-End Reporting Documents

ETAO Announces Appointment of Ryoshin Nakade as ETAO Japan president

PR Newswire

2 years ago

ETAO Announces Appointment of Ryoshin Nakade as ETAO Japan president

Wi-Fi NOW Awards Akoustis and HPE Aruba Networking for Best Enterprise Wi-Fi Solution

GlobeNewswire

2 years ago

Wi-Fi NOW Awards Akoustis and HPE Aruba Networking for Best Enterprise Wi-Fi Solution

Nisun International Reports Unaudited Financial Results for the First Half of 2023

PR Newswire

2 years ago

Nisun International Reports Unaudited Financial Results for the First Half of 2023

Cano Health Announces Appointment of Two New Independent Directors

PR Newswire

2 years ago

Cano Health Announces Appointment of Two New Independent Directors

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

GlobeNewswire

2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

ACCESSWIRE

2 years ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Rent the Runway, Inc. (NASDAQ:RENT) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Rent the Runway, Inc. (NASDAQ:RENT) Q3 2023 Earnings Call Transcript

ACCESSWIRE

2 years ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Newsfile

2 years ago

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

ACCESSWIRE

2 years ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

PR Newswire

2 years ago

Cango Inc. Reports Third Quarter 2023 Unaudited Financial Results

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

ACCESSWIRE

2 years ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 years ago

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Cango Inc. to Report Third Quarter 2023 Financial Results on November 27, 2023 Eastern Time

PR Newswire

2 years ago

Cango Inc. to Report Third Quarter 2023 Financial Results on November 27, 2023 Eastern Time

PR Newswire

2 years ago

Concord Medical Schedules 2023 Annual Meeting of Shareholders

ACCESSWIRE

2 years ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results

GlobeNewswire

2 years ago

Astrotech Reports First Quarter of Fiscal Year 2024 Financial Results

ACCESSWIRE

2 years ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Share on Social Networks: